

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
<u>Company</u>	<u>General</u>
 Merck Sharp & Dohme 	 All Wales Therapeutics and Toxicology
(pembrolizumab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Cancer 52	Department of Health, Social Services
Endometriosis UK	and Public Safety for Northern Ireland
Eve Appeal	Healthcare Improvement Scotland
Go Girls	Medicines and Healthcare products
Helen Rollason Cancer Charity	Regulatory Agency
 Independent Cancer Patients Voice 	 National Association of Primary Care
NA '11 O O 1	National Pharmacy Association
	NHS Confederation
Maggie's CentresMarie Curie	Scottish Medicines Consortium
1 1111111111111111111111111111111111111	
Peaches Womb Cancer Trust	
South Asian Health Foundation	Welsh Health Specialised Services Committee
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	Descible comparator companies
Wellbeing of Women	Possible comparator companies
Womb Cancer Support UK	Accord (carboplatin, paclitaxel)
Women's Health Concern	Alliance Healthcare (paclitaxel)
	Bristol Myers Squibb Pharmaceuticals
Healthcare professional groups	(paclitaxel)
Association of Anaesthetists	Consilient Health (carboplatin)
Association of Cancer Physicians	Fresenius Kabi (carboplatin, paclitaxel)
 Association of Surgeons of Great 	GlaxoSmithKline (dostarlimab)
Britain and Ireland	Hospira UK (carboplatin, paclitaxel)
British Association of Surgical	Pfizer (carboplatin, paclitaxel)
Oncology	 Seacross Pharmaceuticals (paclitaxel)
British Geriatrics Society	Teva UK (carboplatin, paclitaxel)
British Gynaecological Cancer Society	
British Institute of Radiology	Relevant research groups
	Cochrane UK

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207 Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Clinical Cytology British Society for Colposcopy and Cervical Pathology Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians and Gynaecologists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207 Issue date: March 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.